BHVN · Biohaven Ltd.
$14.45
+4.11% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-8.0
Dividend yield
0.0%
Beta
3.20
Avg volume
3M
Employees
0K
Daily Change %
4.11%
5 Days Change
22.29%
10 Days Change
26.99%
30 Days Change
5.23%
60 Days Change
-3.48%
Month to Day Change
5.63%
Year to Day Change
22.94%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BHVN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-23
Latest call per bank · past 12 months
RBC Capital
Sector Perform$22.00
+58.5% vs priceMorgan Stanley
Overweight$19.00
+36.9% vs priceBank of America
Underperform$11.00
-20.7% vs priceCitigroup
Buy$17.00
+22.5% vs priceUBS
Neutral$11.00
-20.7% vs priceJP Morgan
Overweight$15.00
+8.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | RBC Capital | Maintains | Sector Perform | $19.00 → $22.00 |
| 2026-09-10 | HC Wainwright & Co. | Reiterates | Neutral | $10.00 |
| 2026-09-08 | RBC Capital | Downgrade | Outperform → Sector Perform | $23.00 → $19.00 |
| 2026-08-12 | Morgan Stanley | Maintains | Overweight | $18.00 → $19.00 |
| 2026-08-11 | RBC Capital | Maintains | Outperform | $22.00 → $23.00 |
| 2026-06-29 | Bank of America | Downgrade | Neutral → Underperform | $12.00 → $11.00 |
| 2026-05-26 | HC Wainwright & Co. | Reiterates | Neutral | $10.00 |
| 2026-05-13 | Morgan Stanley | Maintains | Overweight | $21.00 → $18.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 7.2% above the 50-day MA ($13.48).
- bullish: Price vs 200-day MA: Trading 19.0% above the 200-day MA ($12.14).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.39) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($7.79) and high ($18.11).
BHVN Price Chart
Loading chart for BHVN…
Fundamentals
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.